Started in Oxford

Since 1997, Oxford University Innovation has been responsible for creating spin-out companies based on academic research generated within and owned by the University of Oxford, and has spun-out a new company every two months on average.

Over £266 million in external investment has been raised by Oxford University Innovation spinouts since 2000, and five are currently listed on London’s AIM market.

The creation of these new spin-out companies also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.

2003

Oxford Consultants for Social Inclusion (OCSI) helps local government identify deprived neighbourhoods, target resources, evaluate programme effectiveness and strengthen regeneration bids.

Incorporated in August 2003

Origin: Oxford University, Department of Social Policy and Intervention

A biotherapeutics company, established to exploit the work in Viral Hepatitis undertaken at Imperial College, London and at Oxford University through the Wellcome Trust Centre for Human Genetics.

Incorporated in July 2003

Origin: Oxford University, Wellcome Trust Centre for Human Genetics

ReOx is a drug discovery company that is building on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).

Incorporated in May 2003

Origin: Oxford University, Centre for Cellular and Molecular Physiology

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Incorporated in February 2003

Origin: Oxford University, Department of Organic Chemistry

2002

BioAnalab offers a contract testing service to the biopharmaceutical industry for the rapidly growing area of therapeutic monoclonal antibodies, with a longer-term strategy to develop diagnostics to measure levels of monoclonal antibodies and their immune response. In July 2009, BioAnaLab was acquired by Millipore Corp.

Incorporated in November 2002

Origin: Oxford University, Department of Pathology

Oxford Risk is the market-leading provider of customer risk profilers. Their products reveal the level of risk customers are willing and able to take with their financial investments.

Incorporated in November 2002

Origin: Oxford University, Nuffield Department of Population Health

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology.

Incorporated in October 2002

Origin: Oxford University, Nuffield Department of Clinical Medicine

Search

Ready to get in touch?

Contact Us
Search
© Oxford University Innovation